Akari Therapeutics, Plc (AKTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $243.76M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-695.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $234.81M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-768.00K.
- 2025-12-31: Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $234.32M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-782.00K.
- 2025-09-30: Common Stock, Value, IssuedUSD $6.52M; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $224.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.14M.
Akari Therapeutics, Plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | (m) | $243.76M | $-695.00K | $-283.81M | $18.59M | (m) | 3 month · $711.00K | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $234.81M | $-768.00K | $-279.00M | $14.38M | (m) | 3 month · $305.00K | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $234.32M | $-782.00K | $-264.55M | $28.33M | (m) | 12 month · $2.89M | 12 month · $1.04M | 12 month · $3.99M | (m) | (m) |
| 2025-09-30 | $6.52M | (m) | $224.37M | $-1.14M | $-259.25M | $22.69M | (m) | 3 month · $685.00K | (m) | (m) | (m) | (m) |
| 2025-06-30 | $6.52M | (m) | $220.85M | $-1.11M | $-252.85M | $25.61M | (m) | 3 month · $719.00K | (m) | (m) | (m) | (m) |
| 2025-03-31 | $5.78M | $215.51M | (m) | $-773.00K | $-250.96M | $21.75M | (m) | 3 month · $1.01M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $5.32M | $212.71M | $212.71M | $-738.00K | $-247.25M | $22.23M | 12 month · $28.00K | 12 month · $2.25M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $2.43M | $183.09M | (m) | $-926.00K | $-243.48M | $-6.69M | 3 month · $26.00K | 3 month · $248.00K | (m) | (m) | (m) | (m) |
| 2024-06-30 | $2.31K | $183.01M | $19.95M | $141.93K | $-42.68M | $-3.70M | (m) | 3 month · $445.00K | (m) | (m) | $0.00 | (m) |
| 2024-03-31 | $1.60M | $176.44M | (m) | $-761.00K | $-233.03M | $-3.55M | 3 month · $3.00K | 3 month · $296.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.32M | $174.75M | $19.92M | $-1.04M | $-227.46M | $-229.00K | 12 month · $4.00K | 12 month · $1.15M | (m) | (m) | $0.00 | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $213.00K | (m) | 3 month · $305.00K | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.01M | $170.85M | (m) | $-825.88K | $-220.45M | $2.78M | 3 month · $1.00K | 3 month · $276.00K 6 month · $541.53K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $6.56M | (m) | 3 month · $265.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.98K | $167.08M | $17.22M | $29.52K | $-25.35M | $1.79M | (m) | 12 month · $452.05K | (m) | (m) | $0.00 | (m) |
| 2022-06-30 | $593.49K | $166.72M | (m) | $-621.56K | $-210.56M | $8.33M | (m) | 3 month · $122.86K 6 month · $221.69K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $13.93M | (m) | 3 month · $98.84K | (m) | (m) | (m) | (m) |
| 2021-12-31 | $475.97K | $153.13M | (m) | $-540.97K | $-199.71M | $-1.94M | (m) | 12 month · $314.65K | (m) | (m) | (m) | (m) |
| 2021-06-30 | $396.50K | $141.88M | (m) | $-420.09K | $-192.47M | $1.59M | (m) | 3 month · $82.10K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $3.94M | (m) | 3 month · $84.89K | (m) | (m) | (m) | (m) |
| 2020-12-31 | $384.73K | $139.73M | (m) | $-648.07K | $-182.28M | $9.38M | (m) | 12 month · $325.52K | 1 month · $3.20M 12 month · $3.20M | (m) | (m) | (m) |
| 2020-09-30 | $46.58M | $136.46M | (m) | $-621.30K | $-175.47M | $6.95M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $46.58M | $136.38M | (m) | $-617.62K | $-176.38M | $5.96M | (m) | 3 month · $63.33K | (m) | (m) | (m) | (m) |
| 2020-03-31 | $40.09M | $132.70M | (m) | $-571.59K | $-168.94M | $3.27M | (m) | 3 month · $100.50K | (m) | (m) | (m) | (m) |
| 2019-12-31 | $31.99M | $133.57M | (m) | $-348.86K | $-165.20M | $7.60K | (m) | 12 month · $1.05M | (m) | (m) | (m) | (m) |
| 2019-09-30 | $30.12M | $132.55M | (m) | $-402.09K | $-157.37M | $4.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $24.54M | $130.81M | (m) | $-405.37K | $-154.49M | $459.37K | (m) | 3 month · $409.62K | (m) | (m) | (m) | (m) |
| 2019-03-31 | $23.72M | $129.91M | (m) | $-245.26K | $-148.54M | $4.84M | (m) | 3 month · $394.44K | (m) | (m) | (m) | (m) |
| 2018-12-31 | $23.65M | $106.62M | (m) | $-352.43K | $-126.80M | $4.37M | (m) | 12 month · $1.65M | (m) | (m) | (m) | (m) |
| 2018-06-30 | $22.93M | $105.63M | (m) | $-230.63K | $-119.70M | $8.63M | (m) | 3 month · $351.98K 6 month · $827.94K | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $16.32M | (m) | 3 month · $475.96K | (m) | (m) | (m) | (m) |
| 2017-12-31 | $22.93M | $104.80M | (m) | $-236.25K | $-110.34M | $22.24M | (m) | 12 month · $2.73M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $18.34M | $92.73M | (m) | $-373.83K | $-87.84M | $22.85M | (m) | 6 month · $1.75M | (m) | (m) | (m) | (m) |
| 2016-12-31 | $18.34M | $90.98M | (m) | $-280.10K | $-74.94M | $34.10M | (m) | 12 month · $3.93M | (m) | (m) | (m) | (m) |
| 2016-06-30 | $18.34M | $88.67M | (m) | $-191.87K | $-66.23M | $40.58M | (m) | 6 month · $1.62M | (m) | (m) | (m) | (m) |
| 2016-03-31 | $18.34M | $87.84M | (m) | $-36.46K | $-59.78M | $46.36M | (m) | 3 month · $816.80K | (m) | (m) | (m) | (m) |
| 2015-12-31 | $18.34M | $87.02M | (m) | $156.48K | $-56.80M | $48.72M | (m) | 12 month · $1.04M | (m) | (m) | (m) | (m) |
| 2015-09-30 | $18.34M | $86.06M | (m) | $197.09K | $-63.27M | $41.33M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $927.00K | $34.22M | (m) | (m) | $-34.18M | $973.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $927.00K | $34.17M | (m) | (m) | $-32.51M | $2.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $11.21M | $2.45M | (m) | $46.08K | $-11.48M | $2.22M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | $10.41M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $675.00K | $25.68M | (m) | $-33.36K | $-20.54M | $400.69K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $245.00K | $13.20M | $13.20M | (m) | $-16.92M | $-3.36M | (m) | (m) | (m) | (m) | (m) | 12 month · $250.00K |
| 2011-12-31 | $225.00K | $9.84M | $9.84M | (m) | $-12.62M | $-2.48M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | $-2.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $-1.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-1.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | $-60.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | (m) | $-467.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | (m) | (m) | $1.23M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2004-10-06 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |